Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05812807
Title Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Alliance for Clinical Trials in Oncology
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | CAN


No variant requirements are available.